Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Benjamin Netanyahu delays judicial reforms after day of turmoil
    • Generative AI set to affect 300mn jobs across major economies
    • Jack Ma returns to China as Beijing seeks to lift confidence in tech sector
    • China’s economic rebound weaker than expected, warns Maersk
    • Pay transparency laws in US stir worker discontent
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Saudi National Bank chair resigns following Credit Suisse comments
      • First Citizens shares surge after Silicon Valley Bank deal
      • European ammunition maker says plant expansion hit by energy-guzzling TikTok site
      • Air India boss hails biggest turnround effort in airline’s history
      • Hedge funds scale back bets against Scottish Mortgage
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from March 27: Netanyahu delays judicial overhaul, First Citizens buys much of SVB
      • Money market funds swell by more than $286bn amid deposit flight
      • Hedge funds scale back bets against Scottish Mortgage
      • Crypto exchange Binance accused by CFTC of illegally serving US clients
      • Italy’s shift away from Russian gas clashes with its climate targets
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A new technology boom is at hand
      • Credit Suisse’s demise: a new twist on the ‘Swiss finish’
      • Why five days in the office don’t add up
      • China, Japan and the Ukraine war
      • Final salary pensions have been uniquely horrible for UK plc
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • My life with Ozempic – a weight-loss diary
      • The best black watches
      • Is France on the road to a Sixth Republic?
      • With slouchy men’s trousers, a little leg goes a long way
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Sanofi SA

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 3 February, 2023
      UK at risk of losing healthcare innovation race with rivals, warns Sanofi boss

      Chief executive Paul Hudson sounds the alarm over British government’s cuts to research

    • Tuesday, 6 December, 2022
      Pharmaceuticals sector
      GSK and Sanofi shares surge after Zantac ruling victory

      US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer

    • Monday, 5 September, 2022
      Sanofi nominates SocGen boss Frédéric Oudéa as chair

      Change comes as French pharma group pours money into immunology and cancer research

    • Wednesday, 17 August, 2022
      Sanofi drops experimental breast cancer drug after second trial fails

      Shares in French pharma group tumble nearly 6% after blow to pipeline of new treatments

    • Thursday, 11 August, 2022
      Pharmaceuticals sector
      Pharma groups lose £30bn of value on heartburn drug lawsuit worries

      Companies face thousands of pending personal injury cases linking Zantac to cancer

    • Friday, 24 June, 2022
      Covid-19 vaccines
      Sanofi-GSK Covid vaccine found effective against Omicron

      Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

    • Monday, 13 June, 2022
      Sanofi and GSK report ‘positive’ results from Covid booster

      ‘Next-generation’ jab delivers strong immune response against variants

    • Tuesday, 17 May, 2022
      Electric vehicles
      Unilever and Sanofi pile on pressure over 2035 EU petrol ban

      Cross-section of companies want to ‘ensure laggards don’t delay the market shift’

    • Wednesday, 23 February, 2022
      Covid-19 vaccines
      Sanofi and GSK to seek approval for delayed Covid vaccine

      Drugmakers to apply for protein-based shot to be used as primary and booster jabs

    • Friday, 4 February, 2022
      Sanofi buoyed by blockbuster eczema drug Dupixent

      French pharma group still working on long-delayed Covid vaccine

    • Wednesday, 15 December, 2021
      Sanofi pushes back expected Covid vaccine approval date again

      French pharma group says jab will probably come to market in first quarter of 2022

    • Tuesday, 28 September, 2021
      Covid-19 vaccines
      Sanofi stops development of Covid vaccine based on mRNA technology

      French group says it is too late to market jab and is working on another with GSK using different technique

    • Tuesday, 3 August, 2021
      Lex
      Sanofi/Translate Bio: do recruit the messenger Premium content

      The acquisition is a sign of the French pharma group’s determination to get back on the podium

    • Tuesday, 3 August, 2021
      Sanofi to buy partner Translate Bio for $3.2bn in mRNA push

      French pharma group tries to catch up with rivals that used the technology to create Covid vaccines

    • Thursday, 29 July, 2021
      Sanofi raises annual profit goal

      French group still aims for its Covid-19 jab to be approved by year end

    • Wednesday, 28 July, 2021
      Coronavirus pandemic
      Coronavirus: Biden reveals mandates and calls for incentives to boost vaccinations - as it happened
    • Tuesday, 29 June, 2021
      Sanofi boosts investment in mRNA to keep pace in vaccines

      French group to open a ‘dedicated mRNA centre of excellence’ after falling behind in Covid-19 jab race

    • Tuesday, 15 June, 2021
      Sanofi agrees to inject tens of millions of pounds into UK pension scheme

      Britain’s pension regulator says French drugmaker began talks after threat of enforcement action

    • Monday, 17 May, 2021
      Covid-19 vaccines
      GSK seeks to make up ground in vaccine race

      UK group and France’s Sanofi release trial data of Covid jab showing strong immune response

    • Friday, 12 March, 2021
      Covid-19 vaccines
      Sanofi to start human trials of mRNA vaccine against Covid-19

      French group has fallen behind newcomers despite being one of the biggest jab makers in world

    • Wednesday, 10 March, 2021
      News in-depthFT Film24 min
      Covid-19 and the business of vaccines

      New vaccine producers and mRNA technology are shaking up the market

    • Tuesday, 16 February, 2021
      News in-depthCovid-19 vaccines
      Why the three biggest vaccine makers failed on Covid-19

      GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

    • Friday, 5 February, 2021
      European companies
      Sanofi to expand cost-savings push to bolster R&D efforts

      French vaccine maker aims to get a Covid-19 shot to market by the fourth quarter

    • Monday, 11 January, 2021
      Lex
      Sanofi/Kymab: reliance on science Premium content

      Deal is latest in string of acquisitions that have given drugmaker access to new technologies

    • Monday, 11 January, 2021
      Sanofi acquires immunotherapy biotech Kymab

      French group also weighs possibility of manufacturing rival Covid-19 vaccines

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In